# Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

> **NCT01505777** · PHASE2 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 280 (estimated)

## Conditions studied

- Irritable Bowel Syndrome Without Diarrhea

## Interventions

- **DRUG:** Probiotics (Medirac)
- **DRUG:** Probiotics (Medirac)
- **DRUG:** Probiotics (Medirac)
- **DRUG:** Probiotics (Medirac)
- **DRUG:** Probiotics (Medirac) placebo/mosapride placebo

## Key facts

- **NCT ID:** NCT01505777
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2013-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01505777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01505777, "Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT01505777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*